Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Heterocyclic compounds as protein kinase inhibitors
US8980911B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980911-B2 |
| Application number | US-201314088093-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2013 |
| Priority date | May 26, 2011 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R 1 , R 2 and R 3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.
First claim
Opening claim text (preview).
We claim: 1. A compound having the structure of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein: A represents CR and B represents N; R and R′ independently represent H, (C 1 -C 6 ) alkyl, halogen, —CN, —NR a R b , —NR a COR b or —CONR a R b ; R″ represents H, halogen or —NR a COR b ;…
Assignees
Inventors
- Verma Ashwani Kumar
- Nagaswamy Kumaragurubaran
- Sharma Lalima
- Ghosh Soma
- Kale Balkrishna Ramchandra
- Mondal Aniruddha
- Srivastava Punit Kumar
- Dastidar Sunanda Ghosh
- Momin Rijwan Jaffer
- Wagh Pradip Balu
- Pansare Sonali Nanasaheb
- Markad Pramod Raosaheb
- Khairnar Yogesh Balasaheb
- Miyauchi Rie
- Murata Takeshi
- Ishizaki Masayuki
- Nagamochi Masatoshi
- Iimura Shin
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980911B2 cover?
- The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R 1 , R 2 and R 3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention p…
- Who is the assignee on this patent?
- Daiichi Sankyo Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/437. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).